Meeting
2011 ASCO Annual Meeting
A national evaluation of response and factors affecting response to neoadjuvant therapy in breast and rectal cancer.
Authors
S. B. Edge
Roswell Park Cancer Institute, Buffalo, NY
S. B. Edge , D. Gress , D. P. Winchester , A. Stewart
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research
Track
Health Services Research
Sub Track
Outcomes Research
Citation
J Clin Oncol 29: 2011 (suppl; abstr 6091)
Abstract #
6091
Poster Bd #
46G
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Peripheral lipidomics analyses with ensemble machine learning predict response to neoadjuvant therapy in breast cancer.
First Author: Jiani Wang
Poster
2022 ASCO Annual Meeting
Prediction of response to neoadjuvant therapy (NAT) in early breast cancer (EBC) at community hospitals: SimBioSys TumorScope Validation Study.
First Author: John R. Pfeiffer
Poster
2020 ASCO Virtual Scientific Program
Comprehensive profiling of androgen receptor-positive (AR+) triple-negative breast cancer (TNBC) patients (pts) treated with standard neoadjuvant therapy (NAT) +/- enzalutamide.
First Author: Bora Lim
Poster
2014 ASCO Quality Care Symposium
An assessment of neoadjuvant therapy for breast cancer and treatment wait times at the BC Cancer Agency Vancouver.
First Author: Rachel Adilman